Gainers
INmune Bio (NASDAQ: INMB) shares are trading higher after the company announced XPro has been found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with AD.
Financial Outlook:
Okta's financial outlook for the third quarter and full year fiscal 2022 includes the expected contribution from the acquisition of Auth0, net of purchase accounting adjustments. The acquisitionFinancial Outlook:
Okta (NASDAQ:OKTA) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.35) by 68.57 percent. This is a 257.14 percent decrease over earnings of $0.07 per share from the same
Shares of Okta (NASDAQ:OKTA) increased by 19.90% in the past three months. Before we understand the importance of debt, let us look at how much debt Okta has.